Taconic Biosciences News

Proven Model Available Exclusively From Taconic Biosciences Rensselaer, NY — November 4, 2019 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, expands its robust neurodegeneration portfolio with the launch of a new Alzheimer's disease model, the ARTE10 mouse model. Exclusively available from Taconic, the ARTE10 is a transgenic mouse model expressing mutant human APP and PS1 genes. This combination manifests in early...  Read More

Dr. Frank Sistare Joins Taconic Biosciences' Scientific Advisory Board Rensselaer, NY — October 17, 2019 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the addition of Frank Sistare, PhD to its Scientific Advisory Board (SAB). Dr. Sistare joins existing SAB members Andrew Goodman, PhD, David Hill, PhD, and Robert Rosenthal, PhD. The SAB will continue to collaborate with Taconic's management in...  Read More

The IP landscape surrounding the use of the CRISPR/Cas9 technology (and variants of it) can pose challenges for model generation. In a recent article published in DDN, Taconic Biosciences' Dr. Caroline Horizny explains the various CRISPR/Cas9 patents and the implications of obtaining patent rights when creating a new animal model for preclinical research: "The CRISPR/Cas9 system, and variants of it, allows for in-vivo modifications including gene knockouts,...  Read More

An article recently published in DDN highlights Taconic Biosciences's new diet-induced NASH mouse model and its importance for preclinical liver disease research. The NASH B6 is available commercially off-the-shelf and available immediately for NAFLD and NASH studies. This level of access enables researchers to test and develop new therapeutics sooner, by skipping the twenty-six weeks needed for other mouse models to develop NASH symptoms once placed on...  Read More

Resulting Studies Will Provide Critical Reference Data to Drive Advancements in Human Health Rensselaer, NY — September 3, 2019 - Taconic Biosciences, a global leader in providing genetically engineered animal model solutions, announces its participation in the second Rodent Research Reference (RRR) mission to the International Space Station. Taconic has a history with NASA dating back to 1985. While previous NASA programs were collaborations with academic and/or...  Read More

Two of Taconic Biosciences's newest products are highlighted in a recent article published in Outsourcing-Pharma. The first, TruBIOME™, is a comprehensive solution to increase reproducibility in mouse models through custom microbial associations. The second is the launch of Taconic's new commercial diet-induced NASH mouse model, which will enable researchers to obtain a model faster for preclinical studies: "As summer heated up, the pharmaceutical industry saw major developments...  Read More

On July 29, 2019, Taconic Biosciences announced the launch of the first commercially-available diet-induced NASH rodent model. These models will help accelerate clinical development of NASH treatments because they are readily-available off-the-shelf at are varying ages already expressing the symptoms of NASH. These models will save researchers months of planning and accelerate the discovery of novel liver failure treatments: "Aiming to speed up and facilitate the clinical...  Read More

In a recent article published in International Biopharmaceutical Industry, Taconic Biosciences' Dr. Alexander Maue highlights the importance of the mouse gut microbiome and its impact on experimental reproducibility. There is an ongoing reproducibility crisis in the research community, and stabilizing the microbiome of a cohort of mice for multiple generations make take away one contributing factor: "Investigators continually seek to improve the reproducibility of their results and...  Read More

New Model Saves Researchers Time as They Study the Devastating Disease Rensselaer, NY — July 29, 2019 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of the first commercially available diet-induced NASH (nonalcoholic steatohepatitis) rodent model. NASH is a dangerous subtype of nonalcoholic fatty liver disease (NAFLD) and has recently garnered increased attention in the biomedical community due to...  Read More

On July 27, 2019, 40 female C57BL6/NTac mice were sent to space on SpaceX's 18th commercial resupply to the International Space Station (ISS). 30 of these mice will be returned to Earth for study, while 10 will remain on the ISS laboratory for additional exposure to microgravity. Studies of mice in space have provided key data about muscle and bone physiology, aging, development, and cardiovascular health: "KENNEDY...  Read More